Krka Spells Out Chinese Potential With Plans To Double Portfolio In 2022

Slovenian Firm Also Plans To Regroup In West Europe After 11% Sales Tumble

Alongside discussing the firm’s preliminary financial results for 2021, Krka management explained how the company planned to make further inroads in China in 2022 and return to its 2020 revenue baseline in West Europe, following a dip last year.

China growth
Krka launched pregabalin in China in 2021 • Source: Shutterstock

“China has the potential to become one of the key markets for Krka Group in the years to come. We already have five products for this market, and we expect 10 by the end of the year,” the Slovenian firm has underlined, as it reported unaudited, estimated financial results for 2021.

“We will be close to a very low two-digit million-euro sales [this year], but we are not there yet,” Krka...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business